Stryker (NYSE:SYK)‘s stock had its “neutral” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Friday. They currently have a $163.00 price target on the medical technology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 1.61% from the company’s current price.
The analysts wrote, “Announced preliminary FY17 revenue of $3.5B, beating FactSet consensus of $3.4B.””
A number of other research analysts have also recently commented on SYK. Royal Bank of Canada reaffirmed a “buy” rating and set a $155.00 price target on shares of Stryker in a research report on Monday, October 2nd. SunTrust Banks reaffirmed a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Monday, October 2nd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $174.00 price target (up previously from $166.00) on shares of Stryker in a research report on Tuesday, January 2nd. They noted that the move was a valuation call. Oppenheimer set a $156.00 price target on Stryker and gave the company a “hold” rating in a research report on Monday, October 30th. Finally, Barclays upped their price target on Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $155.10.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.02. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The firm had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. During the same quarter in the prior year, the firm earned $1.39 EPS. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. sell-side analysts forecast that Stryker will post 6.47 EPS for the current year.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the business. Atlantic Trust Group LLC raised its holdings in shares of Stryker by 1.2% in the 3rd quarter. Atlantic Trust Group LLC now owns 1,186,100 shares of the medical technology company’s stock valued at $168,449,000 after acquiring an additional 13,657 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Stryker by 7.3% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 739,287 shares of the medical technology company’s stock valued at $104,994,000 after acquiring an additional 50,324 shares in the last quarter. AXA raised its holdings in shares of Stryker by 6.5% in the 3rd quarter. AXA now owns 516,156 shares of the medical technology company’s stock valued at $73,304,000 after acquiring an additional 31,375 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of Stryker in the 3rd quarter valued at about $538,000. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Stryker by 0.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 241,591 shares of the medical technology company’s stock valued at $34,311,000 after acquiring an additional 833 shares in the last quarter. 74.90% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Reiterates “Neutral” Rating for Stryker (SYK)” was reported by Slater Sentinel and is the property of of Slater Sentinel. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://slatersentinel.com/news/2018/01/08/stryker-syk-rating-reiterated-by-cantor-fitzgerald.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
